API Prices Are Falling Fast — These 6 Pharma Stocks Were Built for This Moment

API Prices Are Falling Fast — These 6 Pharma Stocks Were Built for This Moment

When crude oil crashed on the back of the US-Iran peace deal, markets immediately rewarded the obvious beneficiaries — paint companies, airlines, and tyre makers. But a quieter, more durable tailwind is building in a sector that spent all of FY26 fighting elevated input costs: pharmaceuticals.

The Economic Times reported on June 16 that active pharmaceutical ingredient (API) prices are falling as West Asia tensions ease. For retail investors, this deserves a closer look — because falling API prices don't just shave a few basis points off pharma costs. They unwind an entire chain of pain: lower crude means cheaper petrochemical-derived solvents and intermediates, easing freight rates mean shorter delivery times and lower logistics bills, and normalized supply chains mean companies stop paying premiums for spot procurement.

Here are six pharma companies whose filings show they were most squeezed by the cost spike — and now stand to gain the most as it reverses.

Aarti Drugs: The Most Direct Crude-to-Margin Link

Aarti Drugs is perhaps the purest play on falling API input costs. In their earnings call, management stated plainly that "65% to 70% of raw material is linked to crude directly or indirectly." Per their Q4 FY26 investor presentation, "FY26 remained challenging due to elevated input cost, crude and gas-based raw material supply chain constraints due to the West Asia war." Freight, packaging, utility, and energy costs all remained elevated through the year.

But the company also noted it "exited the year on a much stronger footing with a sharp sequential recovery in Q4 FY26," driven by process optimization and alternate sourcing. With crude now in retreat, Aarti Drugs stands to benefit on both the cost side (cheaper solvents) and the pricing side — management noted that if crude-linked cost declines persist, "there will be a lot more positive rate variances."

Laurus Labs: Gross Margin Expansion Already Underway

Laurus Labs has been posting improving margins for several quarters, and the numbers in their Q4 FY26 results are striking. Revenue came in at Rs 1,812 crore, with gross margins expanding to 61.4% — up a full 690 basis points year-over-year. EBITDA margin reached 28.9%, and net profit rose 19% to Rs 279 crore, per their Q4 FY26 investor presentation.

The margin story here is partly structural — CDMO (contract development and manufacturing) is a growing share of revenue and carries higher margins. But management confirmed on their earnings call that "as CDMO contribution grows, we expect both gross margin and EBITDA margins should continue to go up." Lower API feedstock costs would amplify this mix shift.

Granules India: Record Revenue, Record Margins, Six Quarters Running

Granules India delivered what management called "a landmark year" in FY26. Revenue hit Rs 53,656 million (roughly Rs 5,366 crore), growing 20% year-over-year with six straight quarters of sequential growth and record gross margins, per their FY26 earnings transcript.

The Q4 FY26 numbers were especially strong: revenue of Rs 14,706 million (+23% Y/Y), EBITDA of Rs 3,521 million (+40% Y/Y) at a 23.9% margin — an improvement of 287 basis points over the prior year, per their Q4 FY26 investor presentation. EBITDA margin expansion was "supported by improved sales and margins" from a better product mix, particularly in finished dosage forms for North America and Europe. With raw material costs set to ease further, Granules' already-record margins have room to expand.

Divi's Laboratories: Backward Integration Paying Off at the Right Time

Divi's Labs has been quietly building cost resilience through backward integration. Their new Unit 3 facility in Kakinada, which began commercial production in January 2025, is "playing a critical role in supporting backward integration strategy, strengthening supply reliability, and driving cost efficiencies," per their Q1 FY26 earnings transcript. The company reported total income of Rs 2,529 crore for Q1 FY26, up 15% from Rs 2,197 crore in Q1 FY25.

Crucially, other expenses (excluding wages) dropped from 17% of sales to 14% — a 300-basis-point improvement driven partly by easing logistics costs. Management noted that "raw material prices have seen a decline and have stabilized" and confirmed that "backward integration as well as the logistics cost easing out" would benefit both gross and EBITDA margins going forward. When API prices fall, backward-integrated producers like Divi's capture the benefit on multiple levels.

Shilpa Medicare: Highest-Ever Quarter Across the Board

Shilpa Medicare has been on a tear. Their Q4 FY26 investor presentation reports the company's highest-ever quarterly revenue at Rs 439 crore, up 30% year-over-year. EBITDA hit Rs 121 crore, growing 40% Y/Y with margins at 28%. Most impressively, adjusted PAT surged 147% to Rs 87 crore.

Earlier in the year, Q1 FY26 showed gross profit margins of 76% — a 700-basis-point expansion year-over-year, per their Q1 FY26 investor presentation. Revenue growth was driven by the company's API and biologics verticals. As a significant API manufacturer with growing formulation capabilities, Shilpa is well-positioned to benefit from both lower input costs on the manufacturing side and steady demand from global buyers restocking after supply disruptions.

Cipla: Large-Cap Resilience with Freight Tailwinds

Among large-cap pharma names, Cipla stands out for both its margin trajectory and its explicit exposure to shipping cost normalization. Reported gross margin after material costs reached 68.8%, expanding 156 basis points year-over-year, per their Q3 FY26 investor presentation. This was "largely attributable to a favorable shift in product mix and strategic portfolio management."

On the logistics front, Cipla's management noted in their earnings call that air freight rates declined 8-9% year-over-year while sea rates dropped a dramatic 60-70%. Their FY26 annual report extensively discusses Middle East supply chain risks — rerouted shipping lanes, port congestion, and elevated freight and insurance costs. As these pressures reverse, Cipla's export-heavy model (with substantial US and South Africa exposure) gets a double benefit: cheaper raw materials and cheaper logistics.

What Retail Investors Should Do

The pharma margin expansion story is different from the immediate oil-crash beneficiaries like paints and airlines. Raw material inventory in pharma typically cycles over one to two quarters, which means the benefit of falling API prices feeds through gradually — it compounds rather than spikes. Companies that reported elevated costs through FY26 (like Aarti Drugs) are the most likely to show sharp margin recovery in Q1 and Q2 FY27 results.

For investors looking at this space, focus on three signals in upcoming quarterly results: (1) gross margin trends versus the prior year, which reveal raw material cost pass-through; (2) management commentary on input cost outlook, especially crude-linked solvents; and (3) other expense ratios, which capture freight and logistics normalization. The companies above have already shown margin improvement — falling API prices could accelerate it.

Data sourced from company filings on NSE via Xaro.